Download PDFPDF
Practical guidance on the use of faecal calprotectin
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Proton Pump Inhibitors may be the cause of an elevated faecal calprotectin.
    • Michael A. Cohen, GP with special interest in Gastroenterology Prime Endoscopy Bristol

    Practical Guidance on the use of faecal calprotectin

    Brookes MJ et al

    Frontline Gastroenterology 2018; 9:87-91

    Dear Sir

    I read this article with interest particularly as I work in a community gastroenterology unit.

    Our unit performs straight to test colonoscopy. We are referred a significant number of

    patients who present with loose motions but do not have alarm symptoms or worrying family

    histories.. Many of them are found to have faecal calprotectin levels which are only slightly

    elevated or in the intermediate range.

    Many of these patients are also taking proton pump inhibitors on a regular basis. A

    colonoscopy is performed and colonic biopsies are taken which are almost always

    normal. A paper, albeit with small numbers of patients, showed that proton pump
    inhibitors may cause a rise in faecal calprotectin levels in normal subjects.

    I recommend that, when it is safe and appropriate to do so, the GP considers stopping

    proton pump inhibitors in such patients and repeats the faecal calprotectin in four weeks.

    The aim here is to avoid unnecessary colonoscopy in a low-risk young patients, most of

    whom have functionally related symptoms. I recent...

    Show More
    Conflict of Interest:
    None declared.